Replies to post #225262 on Biotech Values

[DewDiligence]

ENTA EDP-938—The % reductions relative to placebo for viral-load-AUC (primary endpoint) and symptom-score-AUC (secondary endpoint) were a little lighter than I expected: 73% for the former (average of two dosing arms), and 71% for the latter (average of the two dosing arms).

I’m listening to the CC replay now.